Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Lexaria Bioscience (LEXX) will participate in the 28th Annual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexaria Bioscience (LEXX) will participate in the 28th Annual H.C. Wainwright Global Investment Conference in New York City from September 14–16, 2026. CEO Richard Christopher will deliver a company presentation and hold one-on-one investor meetings, with the presentation also accessible online via a provided link.
Details
News Market Reaction – LEXX
On Sep 4, the day this news came out, LEXX closed 14.85% above the previous close. Argus tracked a peak move of +6.7% during that session. Our momentum scanner recorded 7 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 4 session.
Key Figures
- Conference edition
- 28th annual
- H.C. Wainwright Global Investment Conference
- Conference dates
- September 14-16, 2026
- New York City
- Granted patents
- 66 patents
- Worldwide intellectual property portfolio
Historical Context
-
Australian R&D tax rebate provided USD funding without equity issuance.
-
Animal-study results reported improved absorption for amycretin and retatrutide formulations.
-
PegBio supplied a GLP-1 compound for DehydraTECH formulation and animal testing.
-
One-for-fifteen split targeted Nasdaq minimum bid-price compliance requirements.
-
BIO conference meetings focused on GLP-1 partnerships and DehydraTECH applications.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
oral drug delivery technical
bio-absorption medical
blood brain barrier medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City.
Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link.
Event Details:
Conference: 28th Annual H.C. Wainwright Global Investment Conference
Date: September 14-16th, 2026
Accredited investors interested in scheduling a meeting with the Lexaria management team should contact their H.C. Wainwright representative or email meetings@hcwco.com.
About Lexaria Bioscience Corp. & DehydraTECHTM
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECHTM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECHTM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Lexaria Bioscience (LEXX) present at the H.C. Wainwright 28th Annual Global Investment Conference?
Lexaria Bioscience will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14–16, 2026, in New York City. During this period, CEO Richard Christopher is scheduled to deliver a company presentation and meet with investors.
Who will present for Lexaria Bioscience (LEXX) at the H.C. Wainwright Global Investment Conference?
Richard Christopher, CEO of Lexaria Bioscience, will deliver the company presentation at the H.C. Wainwright 28th Annual Global Investment Conference and will also be available for one-on-one investor meetings throughout the event.
How can investors meet with Lexaria Bioscience (LEXX) during the H.C. Wainwright conference?
Accredited investors can schedule one-on-one meetings with Lexaria’s management team by contacting their H.C. Wainwright representative or by emailing meetings@hcwco.com, as stated for the September 14–16, 2026 conference.
Will Lexaria Bioscience’s (LEXX) presentation at the H.C. Wainwright conference be available online?
Yes. The company states that its presentation at the 28th Annual H.C. Wainwright Global Investment Conference will be available to view online using a provided link.